Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

    NEXT STORY
    Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
    PREV STORY
    Merit Medical Systems to Announce Third Quarter Results on October 28, 2020 and Host “Foundations for Growth” Investor Call on November 10, 2020
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer

    All evaluable patients experienced tumor shrinkageProtocol defined response criteria achieved and trial expansion ongoingWALTHAM, ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection

    The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. ...

    author_avatar
    NASDAQ Market News

    Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy

    author_avatar
    NASDAQ Market News